Axitinib is another TKI, that has been demonstrated to selectively inhibit VEGFR 1-3 and interact with HDAC inhibitors, ultimately leading to the apoptosis of sarcoma tumor cells in vivo and in vitro (176, 179). Here, HDAC9 is linked to sarcoma.